According to Zacks, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. “
Separately, Chardan Capital set a $15.00 target price on Amicus Therapeutics and gave the company a buy rating in a research report on Thursday, August 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $12.19.
Amicus Therapeutics (NASDAQ:FOLD) opened at 7.24 on Tuesday. The company has a 50-day moving average price of $7.26 and a 200-day moving average price of $6.90. The firm’s market cap is $1.03 billion. Amicus Therapeutics has a 12-month low of $4.98 and a 12-month high of $11.78.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. On average, analysts predict that Amicus Therapeutics will post ($1.35) earnings per share for the current year.
In related news, insider Hung Do sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $7.25, for a total transaction of $181,250.00. Following the transaction, the insider now directly owns 558,453 shares of the company’s stock, valued at approximately $4,048,784.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jay Barth sold 10,458 shares of the business’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $7.00, for a total value of $73,206.00. Following the transaction, the insider now directly owns 15,000 shares in the company, valued at $105,000. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Teachers Advisors Inc. increased its stake in Amicus Therapeutics by 1.0% in the first quarter. Teachers Advisors Inc. now owns 173,294 shares of the biopharmaceutical company’s stock valued at $1,464,000 after buying an additional 1,750 shares during the period. BlackRock Fund Advisors increased its stake in Amicus Therapeutics by 1.6% in the first quarter. BlackRock Fund Advisors now owns 5,444,399 shares of the biopharmaceutical company’s stock valued at $46,005,000 after buying an additional 83,654 shares during the period. M&T Bank Corp purchased a new stake in Amicus Therapeutics during the first quarter valued at about $157,000. UBS Group AG increased its stake in Amicus Therapeutics by 37.7% in the first quarter. UBS Group AG now owns 88,282 shares of the biopharmaceutical company’s stock valued at $746,000 after buying an additional 24,155 shares during the period. Finally, Squarepoint Ops LLC increased its stake in Amicus Therapeutics by 101.9% in the first quarter. Squarepoint Ops LLC now owns 83,600 shares of the biopharmaceutical company’s stock valued at $706,000 after buying an additional 42,200 shares during the period. 99.08% of the stock is currently owned by institutional investors and hedge funds.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.